Navigation Links
Model-Based Drug Development 101, a new Xtalks webinar
Date:2/6/2013

Toronto, Canada (PRWEB) February 06, 2013

As the development of new drugs is becomes increasingly expensive and lengthy process, it’s clear that new approaches must be explored.

With model-based drug development (MBDD), mathematical models can be used early on to test extremely complex situations before deciding on a course of action. These models can identify the right dose, the right population, optimize clinical protocol, program, and portfolio designs, and compare candidates with existing drugs — ultimately providing better decisions and optimized returns.

Expert speakers will provide an overview of the basics of model based drug development and its practical applications — from electing the right dose and population to optimizing trial, program, and portfolio design.

Attendees will get a sense of how model- based drug development can help to:

  •     Improve communication across disciplines
  •     Utilize the many data domains to improve drug development
  •     Make better, quantitative, data-driven decisions

A live Q&A with the audience will follow the main presentation.

For more information about this event or to register, http://xtks.in/xto569-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10386010.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
3. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
6. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
7. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
8. Idenix Reports Advancement of HCV Development Pipeline
9. Almost perfect: A breakthrough in superlens development
10. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
11. New Software from SRI Speeds Development of Genome-Scale Models for Drug and Fuel Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... control cells — optogenetics — is key to exciting advances in the study ... spatially patterned light projected via free-space optics stimulates small, transparent organisms and excites ...
(Date:12/8/2016)... Mass (PRWEB) , ... December 08, 2016 , ... ... genetic data bioInformatics portal. In response to client demand KbioBox developed a sophisticated ... edit biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
Breaking Biology Technology:
(Date:12/5/2016)... 5, 2016  The Office of Justice Programs, ... CT Scans Enhance or Replace Medico Legal Autopsies?" ... supporting or replacing forensic autopsies with postmortem X-ray ... In response to recommendations made by The ... CT scans as a potential component of medicolegal ...
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/22/2016)... 22, 2016 According to the new market research ... Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and ... the market is expected to grow from USD 10.74 Billion in 2015 ... between 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):